Author + information
Increased risk of type 2 diabetes noted with statins is at least partially explained by HMG-coenzyme A reductase inhibition. We investigated vascular and metabolic phenotypes of different dosages of rosuvastatin in hypercholesterolemic patients.
This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched among groups. Forty-eight patients were given placebo, and 47, 48, and 47 patients given rosuvastatin 5, 10, and 20 mg, respectively daily during a 2 month treatment period.
Rosuvastatin 5, 10, and 20 mg dose-dependently and significantly improved flow-mediated dilation (34, 40, and 46%) after 2 months therapy when compared with baseline (P<0.001 by paired t-test) or when compared with placebo (P<0.001 by ANOVA), and increased insulin (median % changes; 16, 20, and 20%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2 months therapy when compared with either baseline (all P<0.05 by paired t-test), or when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA).
Rosuvastatin treatment dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients.